Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026
Freenome will present late-breaking validation data for its updated SimpleScreen CRC blood test at the ACG 2026 Annual Meeting on Oct. 14. The updated test showed 18.2% sensitivity for advanced precancerous lesions, up from 13.7% previously, and 41.9% for high-grade dysplasia lesions versus 30.5% — described as the highest reported for any non-invasive screening blood test in a pivotal registrational study. Overall CRC detection held at 80.4% sensitivity with 90% specificity.
Key figures
- Drug Name
- SimpleScreen CRC
- Specificity
- 90%
- Crc sensitivity
- 80.4%
- Apl sensitivity prior
- 13.7%
- Hgd sensitivity prior
- 30.5%
- Apl sensitivity updated
- 18.2%
- Hgd sensitivity updated
- 41.9%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.